Cost-effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-small Cell Lung Cancer in Greece
**Background:** Non-small cell lung cancer (NSCLC), which accounts for about 80%-85% of lungcancer cases, is a leading cause of cancer-related death worldwide. Lorlatinib is a potent third-generation anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of patients with advanced, ALK...
Saved in:
Main Authors: | George Gourzoulidis, Oresteia Zisimopoulou, Nadia Boubouchairopoulou, Christina Michailidi, Chrissy Lowry, Charalampos Tzanetakos, Georgia Kourlaba |
---|---|
Format: | Article |
Language: | English |
Published: |
Columbia Data Analytics, LLC
2022-02-01
|
Series: | Journal of Health Economics and Outcomes Research |
Online Access: | https://doi.org/10.36469/jheor.2022.32983 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Anaplastic Lymphoma Kinase-Negative Anaplastic Large Cell Lymphoma with Colon Involvement
by: Yuko Sakakibara, et al.
Published: (2015-01-01) -
An Anaplastic Lymphoma Kinase-positive Inflammatory Myofibroblastic Tumor with Rapidly Acquired Resistance to First-line Anaplastic Lymphoma Kinase Inhibitor: A Case and Literature Review
by: Shu-Cheng Wu, et al.
Published: (2024-01-01) -
Pathobiology of Anaplastic Large Cell Lymphoma
by: Pier Paolo Piccaluga, et al.
Published: (2010-01-01) -
Primary Breast Anaplastic Large-Cell Lymphoma
by: Min-Hong Wang, et al.
Published: (2023-10-01) -
Anaplastic, T-Cell, Non-Hodgkin's Lymphoma Presenting with Haematuria
by: C. Blick, et al.
Published: (2008-01-01)